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Abstract
Background: The Intratumoral Microvessel Density (IMVD) is commonly used to quantify tumoral vascularization
and is usually assessed by pan-endothelial markers, such as CD31. Endoglin (CD105) is a protein predominantly
expressed in proliferating endothelium and the IMVD determined by this marker measures specifically the
neovascularization. In this study, we investigated the CD105 expression in pediatric rhabdomyosarcoma and
assessed the neovascularization by using the angiogenic ratio IMVD-CD105 to IMVD-CD31.
Methods: Paraffin-embedded archival tumor specimens were selected from 65 pediatric patients affected by
rhabdomyosarcoma. The expression levels of CD105, CD31 and Vascular Endothelial Growth Factor (VEGF)
were investigated in 30 cases (18 embryonal and 12 alveolar) available for this study. The IMVD-CD105 to
IMVD-CD31 expression ratio was correlated with clinical and pathologic features of these patients.
Results: We found a specific expression of endoglin (CD105) in endothelial cells of all the rhabdomyosarcoma
specimens analyzed. We observed a significant positive correlation between the IMVD individually measured
by CD105 and CD31. The CD105/CD31 expression ratio was significantly higher in patients with lower survival
and embryonal histology. Indeed, patients with a CD105/CD31 expression ratio < 1.3 had a significantly increased OS
(88%, 95%CI, 60%–97%) compared to patients with higher values (40%, 95%CI, 12%–67%). We did not find any
statistical correlation among VEGF and EFS, OS and CD105/CD31 expression ratio.
Conclusion: CD105 is expressed on endothelial cells of rhabdomyosarcoma and represent a useful tool to quantify
neovascularization in this tumor. If confirmed by further studies, these results will indicate that CD105 is a potential
target for combined therapies in rhabdomyosarcoma.
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Background
Rhabdomyosarcoma (RMS) is the most common type of
soft tissue sarcoma (STS) in children and young adults,
accounting for up to 5% of all childhood cancers and for
about 40% of pediatric STS [1]. Embryonal (ERMS) and
alveolar (ARMS) RMS are the two major histologic sub-
types. ARMS is associated with PAX3/7-FOXO1 gene
fusions and with a poor prognosis, often being meta-
static at diagnosis [2]. Although during the last three
decades, multimodal treatment strategies have substan-
tially improved the prognosis of localized RMS, for
metastatic disease the prognosis remains dismal [3].
Therefore, new targets and tailored therapies directed
against the metastatic process are needed for these
patients. The formation of new blood vessels is a re-
quirement for tumor growth and metastatic spread and
many regulators of tumor angiogenesis have been identi-
fied in different types of cancer [4]. Studies on inhibitors
of angiogenesis have shown antitumor activity in
pediatric sarcoma models, including RMS, mostly in
combination with other drugs [5–7], and several trials
showed promising results for selected clinical indications
[8–10]. The quantification of tumor vasculature is a
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useful indicator of angiogenesis, by helping patients
stratification prior to anti-angiogenic therapy and moni-
toring patient response. One often-quantified aspect of
tumor vasculature is the Intratumoral Microvessel Dens-
ity (IMVD). IMVD is commonly used as a surrogate
marker to quantify angiogenic activity and is usually
assessed by pan-endothelial markers, such as CD34 and
CD31 [10–13]. However, these markers are not tumor
endothelial-specific, as they are also expressed on pre-
existing/mature vasculature and on large vessels [14, 15].
Recent studies have shown that IMVD assessed by detec-
tion of Endoglin (CD105) is more specifically associated
with tumor neovascularization [16–20] and represents a
significant prognostic marker in several tumors [19–24].
CD105 is a transforming growth factor β (TGF-β) trans-
membrane co-receptor required for angiogenesis [25] and
is highly expressed on the surface of actively proliferating
microvascular endothelial cells, forming immature, highly
permeable tumor neovessels [26]. In line with its supportive
role in tumor neoangiogenesis, CD105 is up-regulated by
hypoxia [27–29]. The expression of CD105 has been re-
ported on the tumor vasculature of several sarcomas, in-
cluding Kaposi sarcoma, angiosarcoma, leiomyosarcoma,
chondrosarcoma and gastrointestinal stromal tumor and
correlated with worse survival for some of these tumors
[21, 30–33]. In this study, we aimed to investigate if CD105
was expressed in pediatric RMS and assess the neovascu-
larization by using the angiogenic ratio IMVD-CD105 to
IMVD-CD31. For this purpose, we evaluated the immuno-
histochemical expression of CD105, CD31 and VEGF in a
retrospective series of pediatric patients with RMS. In order
to define the proliferation fraction of the endothelium we
compared the CD105 microvessels count with CD31
immunoexpression obtaining the CD105/CD31 expression
ratio. In the cases where the CD105/CD31 expression ratio
is higher, the angiogenesis is increased because CD105
marks the neoformed vessels [26] whereas CD31 is also
expressed in mature vessels [18]. This ratio has been re-
ported to have a prognostic value and be a potential pre-
dictor of response to anti-VEGF therapy [34–36].
Methods
Study population
Tumor tissue specimens from 65 patients with RMS who
underwent surgical resection or biopsy of their primary
tumor at the Bambino Gesù Children’s Hospital from
2005 to 2016 were retrospectively reviewed. Among these,
we selected 30 appropriate paraffin embedded tissue
blocks. The criteria for selecting the patients were based
on the availability of an adequate tumor specimens ob-
tained before any treatment and detailed clinical informa-
tion. Patients’ clinical details, information on therapy and
follow-up were collected retrospectively from the medical
files. The median age at diagnosis was 48.5 months (range
1–199) with a sex ratio of 1. The most frequent primary
site was head and neck (6 parameningeal and 2 non para-
meningeal patients respectively), followed by orbit (5
patients), pelvis (4 patients), genitourinary non-bladder or
prostate (3 patients), extremity (2 patients), genitourinary
bladder or prostate (1 patient), and other localizations (7
patients). This series include 18 patients with ERMS and
12 with ARMS. The study was approved according to
local institutional guidelines.
Patient variables analyzed
Patient- and tumor-related prognostic factors considered
were: age at diagnosis (favorable if ≥ 12 or < 120 months
and unfavorable if <12 or ≥ 120 months), primary tumor
size (≤ 5 cm versus > 5 cm), tumor site favorable (orbit,
genitourinary non bladder/prostate, head and neck non
parameningeal) and unfavorable (parameningeal, ex-
tremities, genitourinary bladder-prostate and “other
site”), histology (embryonal versus alveolar) and COG
risk stratification [37].
Immunohistochemistry methods
The tissues were fixed with 10% formalin and embedded
in paraffin. Consecutive 2.5 μm-thick serial sections were
cut, deparaffinised in xylene, rehydrated and washed using
double distilled water. These sections were used for im-
munohistochemical staining for CD105, VEGF and CD31
and human tonsils were used as positive controls for
CD105, CD31 and VEGF. For staining with VEGF and
CD31, sections were pretreated with DAKO PT link
(PT200) in low pH solution (cod. K8005 DAKO North
America, CA) for antigen retrieval. As for CD105, sections
were pretreated with Proteinase K (cod. S3020 DAKO
North America, CA) for 10 min at room temperature.
The immunostaining was done at 4 °C overnight using the
following monoclonal mouse anti-human antibodies as
primary antibody: anti-CD105 (clone SN6h, 1:10, DAKO
North America, CA), anti-VEGF (MS-1467-P, 1:200,
Thermo Fisher, Fremont, CA), anti-CD31 (IR610, Ready-
to-Use, DAKO North America, CA). As the secondary
antibody, we used En Vision Flex/HRP (cod. K8024,
Ready-to-Use, DAKO North America, CA). The sections
were then reacted in chromogen 3,3’-diaminobenzidine to
detect the peroxidase activity, counterstained with
hematoxylin and mounted.
Measurement of IMVD
Hematoxylin-Eosin staining has been used by an experi-
enced pathologist (RB) in order to select the area of the
tumor, the necrotic areas were excluded. The sections
were examined using a double-headed light microscope
(Leica DM4 B) by two independent operators (RB and
VDP), who were not aware of the clinical status of the
patients. IMVD was assessed by immunostaining for
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either CD31 (IMVD-CD31) or CD105 (IMVD-CD105)
according to the procedure described by Weidner et al.,
[11, 38]. The most vascularized area (hot-spots) was
identified at low magnification (40X) and then three
fields were counted at high magnification (20X). We
considered as a countable single microvessel any endo-
thelial cell or endothelial-cell cluster stained and clearly
separated from the adjacent microvessels, tumor cells
and other connective-tissue elements. The mean of the
vessels in three fields was used as CD105 IMVD or
CD31 IMVD. CD105 IMVD and CD31 IMVD have been
evaluated in two different serial slides, within the same
“hot spot” area. In order to define the proliferation
fraction of the endothelium, we calculated the CD105/
CD31 ratio dividing the IMVD of CD105 by the IMVD
of CD31, as previously described [34–36]. Indeed, since
CD31 is a pan-endothelial marker and CD105 is primar-
ily expressed by proliferating endothelial cells, this ratio
specifically measures the fraction of proliferating
endothelial cells.
Evaluation of VEGF
The VEGF expression was estimated according to the
percentage of immunoreactive cells in a total of 1000
cells. The tumors were classified into 4 categories based
on VEGF staining: negative (0), weak (1+), moderate (2
+) and strong (3+). The percentage of positive cells was
defined as sporadic (positive cells ≤ 1% and < 10%), focal
(positive cells ≤ 10% and < 50%) or diffused (positive
cells ≥ 50%). The immuno-histochemical scores were
recorded as score 0 (no immunoreactivity), score 1 (1+
with sporadic or focal distribution), score 2 (1+ with
diffused distribution or 2+ or 3+ with sporadic distribu-
tion), score 3 (2+ with focal or diffused distribution),
score 4 (3+ with focal or diffused distribution) [39].
Statistical analysis
Categorical data was represented as counts and propor-
tions, and continuous data as mean and standard devi-
ation or median and range. We analyzed the overall
survival (OS) and event-free survival (EFS) defined as
the time from diagnosis until the date of death and the
date of disease relapse/progression, respectively. The
follow-up period was calculated from the date of diagno-
sis until the last follow-up visit. Correlation between
CD105 and CD31 IMVD was examined using the Spear-
man’s Rho. The ROC (Receiving operation curve)
analysis was used in order to find an appropriate cut-off
of CD105/CD31 ratio discriminating between death and
survival, and event (disease relapse/progression) and non
event in terms of sensibility and specificity.
Univariable analysis of time to event data (OS and
EFS) was performed through the Kaplan Meier method,
Log-rank test and Cox proportional hazard model.
Relationships between the CD105/CD31 ratio and
clinico-pathological data were assessed using univariable
quantile regression analysis. P values less than 0.05 were
considered to be statistically significant. Data was ana-
lyzed using the STATA software version 13.1.
Results
Clinico-pathological features of RMS patients
Patients’ characteristics are detailed in Table 1.
Patients were staged according to COG-STS risk stratifi-
cation [37]. PAX3/PAX7-FKHR fusion gene transcripts
were evaluated in 9 cases of 12 ARMS and 9 cases of 18
ERMS. PAX3-FKHR fusion gene was positive in 8 ARMS
cases, and PAX7-FKHR in 1 ARMS case. None of PAX3/
PAX7-FKHR fusion gene was detected in the ERMS ex-
amined. The median follow-up of patients was 5 years
(range 0.28–11.12 years). Eight patients died of disease
(median time from diagnosis 16.5 months, range 5–64).
Patients #6, #17 and #24 presented a short follow-up since
they died after 5, 7 and 10 months respectively due to
rapid disease progression. The immunostaining was per-
formed on pretreatment tumor biopsy specimens. The ex-
pression of CD31 and CD105 was localized in endothelial
cells in all the specimens analyzed and not expressed by
tumor cells. In the tumor CD105 was specifically associ-
ated with immature vessels which showed a stronger posi-
tivity compared to the large vessels (Additional file 1:
Figure S1). VEGF expression was detected mainly in the
cytoplasm of the tumor cells or endothelium (Fig. 1).
Nineteen tumors (63.3%) showed a VEGF staining score of
1–2, while 11 (36.7%) showed a score of 3–4.
The ratio of IMVD-CD105 to IMVD-CD31 in RMS primary
samples
Analysis of CD105 and CD31 expression demonstrated
that the average of CD105-IMVD was not statistically,
significantly higher than CD31-IMVD in RMS tissue (P
= 0.122 Wilcoxon signed-rank test). We observed a
statistically significant positive correlation between the
IMVD individually measured by the two markers (Spear-
man’s rho = 0.86, P = 0.05), (Fig. 2). CD105/CD31 expres-
sion ratio in the tumor specimens ranged from 0.32% to
2.35%, with a median value of 1% and a mean of 1.15%
(Table 1). The ROC curve analysis was used to deter-
mine the optimal cut-off of CD105/CD31 ratio (Fig. 3).
EFS showed a cut-off point value of 0.9 with a 90.9%
sensitivity and 52.6% specificity (Fig. 3a). OS had a cut-
off point value of 1.3 with a 71.4% sensitivity and 78.2%
specificity (Fig. 3b). Our analysis demonstrated that ten
patients with a CD105/CD31 expression ratio equal or
higher than 0.9 (50% of patients in this group) had
relapse or disease progression. Only one patient (#6)
with a ratio lower than 0.9 (10%) experienced disease
progression, but had metastatic disease, which is per se a
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poor prognostic factor. These results suggest that the
CD105/CD31 expression ratio in the primary tumor
could be associated with disease aggressiveness.
Correlation between prognostic factors and outcome in
RMS patients
We then investigated the relationship amongst EFS or OS,
selected prognostic clinico-pathological parameters (age at
diagnosis, tumor size, primary site, histology, COG risk
stratification) and the angiogenic CD105/CD31 ratio. As
summarized in Table 2, the EFS and OS of patients with
high risk RMS, according to COG stratification, resulted
dismal, as it was previously reported [37].
Furthermore, in the univariable Cox proportional
hazard regression the CD105/CD31 expression ratio
resulted to be related with decreased OS (P = 0.03) [38].
Relationship of CD105/CD31 expression ratio with
clinico-pathological characteristics and outcome
Based on ROC curves cut-off values, Kaplan-Meier ana-
lysis showed that patients with a value of the CD105/
CD31 expression ratio < 1.3 had a significantly increased
OS (88%, 95%CI = 60%–97%) compared to patients with
Table 1 Characteristics of the 30 patients with Rhabdomyosarcoma
Pt Age
(mos)











1 83 M ARMS Extremity > 5 No N0 III Intermediate HR/G NED 1.1611
2 65 F ERMS Pelvis > 5 No N1 III Intermediate HR/F NED 0.6825
3 43 M ERMS Abdomen > 5 No N0 III Intermediate HR/E NED 0.7466
4 82 F ARMS Extremity > 5 No N0 III Intermediate HR/G NED 1.0460
5 55 M ERMS GU non BP ≤ 5 No N0 I Low LR NED 1.4292
6 41 M ERMS Orbit > 5 Bone/BM N0 IV High META DOD 0.5133
7 28 F ARMS HN PM ≤ 5 No N0 II Intermediate HR/G NED 1.4225
8 13 M ARMS Orbit ≤ 5 No N0 III Intermediate HR/G NED 1.7949
9 11 F ERMS HN PM ≤ 5 No N1 III Intermediate HR/F DOD 1.3006
10 37 F ERMS GU non BP ≤ 5 No N0 III Low SR/C NED 0.8942
11 116 F ERMS Pelvis > 5 Lung Nx IV High META DOD 1.0158
12 176 M ARMS Retroperitoneum > 5 Lung N1 IV High META DOD 1.5517
13 48 F ERMS GU BP > 5 No N0 III Intermediate HR/E NED 1.8627
14 49 F ARMS HN PM > 5 No N1 III Intermediate VERY HR NED 1.2461
15 17 M ARMS HN non PM ≤ 5 No N0 II Intermediate HR/G NED 1.0354
16 1 M ERMS Pelvis > 5 No N0 II Low HR/E NED 0.8868
17 1 F ARMS HN PM ≤ 5 Multipleb N1 IV High META DOD 1.5608
18 16 F ARMS Chest wall ≤ 5 No N0 II Intermediate HR/G NED 0.8651
19 24 M ARMS Orbit ≤ 5 No N0 III Intermediate HR/G DOD 2.0024
20 135 M ARMS Chest wall > 5 No N1 III Intermediate VERY HR DOD 1.9190
21 26 F ERMS Biliary tracts ≤ 5 No N0 III Low SR/D NED 1.1058
22 97 M ERMS Orbit > 5 No N0 III Low SR/C NED 1.0274
23 154 M ERMS Orbit > 5 No N0 II Low SR/C AWD 0.9020
24 14 F ERMS Abdomen > 5 No N1 I Low HR/F DOD 2.3542
25 23 F ERMS Pelvis > 5 Lung/Bone N1 IV High META NED 0.7117
26 199 F ERMS HN PM > 5 No N0 III Intermediate HR/E AWD 0.9333
27 176 M ARMS GU non BP ≤ 5 Bone N1 IV High VERY HR NED 0.5914
28 106 F ERMS HN PM > 5 No N1 III Intermediate HR/F AWD 1.0217
29 146 M ERMS HN non PM > 5 No N1 III Low HR/F AWD 0.7733
30 189 M ERMS Extremity > 5 No N0 III Intermediate HR/E AWD 0.3281
(Pt patient, mosmonths, M male, F female, ARMS alveolar rhabdomyosarcoma, ERMS embryonal rhabdomyosarcoma, GU non BP genitourinary non-bladder or prostate,
HN non PM head and neck non-parameningeal, GU BP genitourinary bladder or prostate, HN PM Head and neck parameningeal, BM bone-marrow, N0 no clinical or
pathological node involvement, N1 clinical or pathological nodal involvement, NX No information on lymph node involvement, HR High Risk, METAmetastatic, LR Low
Risk, SR Standard Risk, NED no evidence of disease, DOD died of disease, AWD alive with disease, a: post-surgical stage according to Intergroup Rhabdomyosarcoma
Study (IRS) grouping system41; b: subcutaneous, liver, pancreas, lung, bone-marrow and paravertebral lesion at L2-L3 level; COG, Children’s Oncology Group)
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higher values (40%, 95%CI = 12%–67%; P = 0.013 by the
log-rank test), (Fig. 4b). The estimated 5-year EFS was
91% (95%CI = 51%–98%) for patients with a CD105/
CD31 ratio lower than 0.9 compared with 45% (95%CI =
22%–65%) for those with a ratio higher or equal to 0.9
(P = 0.054 by the log-rank test) (Fig. 4a). We further
evaluated VEGF expression in order to correlate this
marker, which is upregulated in RMS [39–43], with the
neo-angiogenic ratio. Determinants of CD105/CD31 ex-
pression ratio were assessed by univariable quantile re-
gression analysis (Table 3). This ratio was significantly
associated with the patients’ survival (P = 0.016) and the
embryonal histology (P = 0.019).
Discussion
Neo-angiogenesis has long been implicated in generating
a microenvironment suitable for tumor growth and
metastatic spread [44]. Several pro-angiogenic factors
have been described and among them VEGF appears to
play a central role in the activation of angiogenesis in
various cancer [45, 46]. Several efforts have been made
to develop therapies focused on the inhibition of the
Fig. 1 Representative immunostaining for CD105, CD31and VEGF of ARMS and ERMS. Magnification × 200
Fig. 2 Correlation between CD105-IMVD and CD31-IMVD in rhabdomyosarcoma tumor samples (R2 = 0.83, P < 0.001)
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VEGF signaling pathway also in RMS [47, 48]. However
these drugs led to transient responses and the comple-
mentary/dual inhibition of non-VEGF angiogenic path-
ways might represent a way to improve anti-angiogenic
therapy. A phase I study using an anti-endoglin mono-
clonal antibody (TRC105) in combination with bevacizu-
mab in adults with advanced cancers showed good
tolerance and clinical activity in a VEGF inhibitor-
refractory population [49]. A trial testing TRC105 in
combination with pazopanib in patients with STS
(≥12 years old) is currently ongoing [50]. In this context,
methods which enable to quantify tumor angiogenesis
are useful surrogate markers of angiogenic activity and
response to therapy, and might help stratify patients
with RMS for treatment. The IMVD is the most com-
monly used parameter to quantify intra-tumoral
neovascularization and is measured by pan-endothelial
markers, such as CD31. CD105 presents a higher specifi-
city for new developing vessels and recent studies have
shown that IMVD as determined by this marker has a
higher prognostic impact than CD31 in several tumors
[21–23]. In particular, IMVD ratio of CD105/CD31
expression, had been used to specifically assess neovas-
cularization showing a prognostic value [34–36]. In the
present study, we analyzed for the first time, the CD105
immunoexpression in pediatric RMS and quantified the
presence of proliferating endothelial cells by using the
CD105/CD31 expression ratio. CD105 was detected in
small tumor capillary-like vessels, whereas CD31 pre-
sented a more diffused expression in endothelial cells.
The significant positive correlation found between the
IMVD measured by the two markers is coherent with
Fig. 3 ROC analysis of CD31/CD105 ratio regarding Event-Free survival (a) and Overall survival (b)
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the association between CD105 expression and other
endothelial markers, such as CD31 and CD34, already
described in other tumors [51, 52]. We also evaluated
whether a correlation between this neoangiogenic ratio
and clinic-pathological variables exists. Several prognos-
tic factors, such as the age at diagnosis, primary tumor
size, primary site, histology, post-surgical stage and pres-
ence or absence of distant metastases are currently used
for risk-adapted treatment approaches in clinical trials of
RMS patients [53]. Using these parameters, in the uni-
variable survival analysis, we found that the advanced
disease, classified according to the COG risk stratifica-
tion, was a significant predictor of worse OS and EFS. In
line with previously reported works, our study confirms
that metastatic disease is the main prognostic factor in
RMS [3]. The ROC curve for the OS indicated a cutoff
point of 1.3, which was used to separate patients with
good and poor prognosis. A value of the CD105/CD31
expression ratio < 1.3 was associated with a significantly
better patients’ OS. These findings suggest that neovas-
cularization could be an indicator of prognosis in
patients with RMS and are supported by the correlation
described between the CD105/CD31 expression ratio
and aggressive phenotypes in other tumors [35]. Indeed,
it has been already reported that IMVD quantified by
CD105 correlate with poor survival in patients with
breast carcinoma, non-small cell lung cancer and hepa-
tocellular carcinoma [13, 54, 55]. Interestingly, when the
histotype was specifically considered, we found that the
ERMS correlated significantly with neo-angiogenesis.
Kuda et al., previously described that IMVD, assessed by
CD31, was higher in ERMS than ARMS [56]. We specu-
late that this association could be related to the different
growth rate displayed by these two RMS histotypes.
Indeed, although angiogenesis is a key process activated
during cancer invasion and metastasis, highly aggressive
histotypes are also able to support their growth through
a process known as vasculogenic mimicry (VM) [57].
Table 2 Univariable Cox proportional hazards regression for Event Free Survival and Overall Survival
Variables EFS OS
Hazard ratio IC (95%) P Hazard ratio IC (95%) P
Age at diagnosis
≥ 1 < 10 (ref ) – – – – – –
< 1≥ 10 2.58 0.78;8.53 0.121 3.02 0.74; 12.25 0.121
Histology
ARMS (ref ) – – – – – –
ERMS 0.63 0.19; 2.06 0.443 0.86 0.21; 3.46 0.831
Tumor size
≤ 5 cm (ref ) – – – – – –
> 5 cm 1.66 0.44;6.28 0.453 2.17 0.43; 10.87 0.344
Primary site (location)
Favorable (ref ) – – – – – –
Unfavorable 1.11 0.32;3.80 0.867 1.14 0.27; 4.80 0.851
COG Group
Low (ref ) – – – – – –
Intermediate 2.93 0.35;24.41 0.319 1.13 011; 10.98 0.914
High 9.76 1.04;91.19 0.046 11.59 1.19; 112.25 0.034
VEGF score
1–2 (ref ) – – – – – –
3–4 0.54 0.14;2.06 0.373 0.46 0.93; 2.31 0.349
CD105/CD31 Ratio
< 0.9 (ref ) – – – – – –
≥ 0.9 5.31 0.75;46.25 0.090 – – –
CD105/CD31 Ratio
< 1.3 (ref ) – – – – – –
≥ 1.3 – – – 5.89 1.18;29.2 0.030
(Ref Reference, IC interval confidence, COG Children’s Oncology Group, ERMS embryonal rhabdomyosarcoma, ARMS alveolar rhabdomyosarcoma, VEGF Vascular
Endothelial Growth Factor, CD105 Endoglin). In boldface the values statistically significant
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The generation of non-endothelialized vessel-like chan-
nels allows the perfusion of a variety of tumors, enabling
them to aggressively proliferate and metastasize [58].
The VM channels are not lined by endothelial cells, but
by tumor cells instead, and therefore are not stained by
endothelial markers, including CD31 [59]. A higher inci-
dence of VM has been described in tumors presenting
necrosis, as well as in ARMS, and has been associated
with poor prognosis [60, 61]. The faster growth of
ARMS compared to ERMS may explain the different
pattern of neovessels in the two variants. No statistically
significant differences in CD105/CD31 expression ratio
were encountered with respect to age, tumor size,
primary tumor location, COG risk groups and VEGF.
Despite VEGF overexpression has been reported to be
associated with prognosis in RMS patients [42], data
regarding the correlation amongst IMVD, VEGF expres-
sion and prognosis has shown conflicting results in
several tumors including STS and RMS [39, 56, 62–64].
In conclusion, this small proof-of-concept study sug-
gests that CD105 is expressed in endothelial cells of
pediatric RMS and that CD105/CD31 expression ratio
might be useful to measure the proportion of proliferat-
ing endothelial cells in this tumor. Despite the small
cohort of patients studied, these data indicate that a
high value of CD105/CD31 expression ratio could be
related with a “pro-angiogenic” RMS subset of patients
with low OS.
Conclusions
If further studies confirm these results in larger cohorts
of patients, CD105 may also represent a potential
Fig. 4 Kaplan-Meier curve for Event-Free survival (a) and Overall survival (b) according to CD105/CD31 ratio groups
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therapeutic target as part of combined therapy in RMS.
In particular, an inter-institutional cooperative study
would be advisable considering the low frequency of this
tumor in the pediatric population. This type of large
study could also be a tool to elucidate if the CD105/
CD31 expression ratio may be useful for patient’s strati-
fication and/or evaluate response to therapy.
Additional file
Additional file 1: Figure S1. Immunostaining of CD105 for ERMS and
ARMS. Magnification × 200. (PDF 266 kb)
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